Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Reed

Showing results (201-210 of 263) with videos related to

Pageof 27
Sort By:
Tuberculosis (Edinburgh, Scotland)|December 31, 2022
Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimenMaham Rais, Hazem Abdelaal, Valerie A Reese, et al.
BMC Infectious Diseases|July 23, 2013
High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasisFabrícia Alvisi de Oliveira, Carla Vanessa Oliveira Silva, Nayra Prata Damascena, et al.
Veterinary Immunology and Immunopathology|September 3, 2021
Novel polyprotein antigens designed for improved serodiagnosis of bovine tuberculosisKonstantin P Lyashchenko, Alina Sikar-Gang, Archana A Sridhara, et al.
Parasites & Vectors|July 6, 2016
Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasisPrakash Ghosh, Khondaker R H Bhaskar, Faria Hossain, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Vaccine|November 3, 2009
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasisIván D Vélez, Katherine Gilchrist, Sofía Martínez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
Clinical and Vaccine Immunology : CVI|October 6, 2017
Identification of Novel Antigens Recognized by Serum Antibodies in Bovine TuberculosisKonstantin P Lyashchenko, Adrian Grandison, Karen Keskinen, et al.
Infection and Immunity|June 22, 2011
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsionJoanne M Lumsden, Sathit Pichyangkul, Utaiwan Srichairatanakul, et al.
Vaccine|September 21, 2010
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasisAlejandro Llanos-Cuentas, Wessmark Calderón, María Cruz, et al.
Pageof 27

Showing results (201-210 of 263) with videos related to

Sort By:
Pageof 27
Tuberculosis (Edinburgh, Scotland)|December 31, 2022
Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimenMaham Rais, Hazem Abdelaal, Valerie A Reese, et al.
BMC Infectious Diseases|July 23, 2013
High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasisFabrícia Alvisi de Oliveira, Carla Vanessa Oliveira Silva, Nayra Prata Damascena, et al.
Veterinary Immunology and Immunopathology|September 3, 2021
Novel polyprotein antigens designed for improved serodiagnosis of bovine tuberculosisKonstantin P Lyashchenko, Alina Sikar-Gang, Archana A Sridhara, et al.
Parasites & Vectors|July 6, 2016
Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasisPrakash Ghosh, Khondaker R H Bhaskar, Faria Hossain, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Vaccine|November 3, 2009
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasisIván D Vélez, Katherine Gilchrist, Sofía Martínez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
Clinical and Vaccine Immunology : CVI|October 6, 2017
Identification of Novel Antigens Recognized by Serum Antibodies in Bovine TuberculosisKonstantin P Lyashchenko, Adrian Grandison, Karen Keskinen, et al.
Infection and Immunity|June 22, 2011
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsionJoanne M Lumsden, Sathit Pichyangkul, Utaiwan Srichairatanakul, et al.
Vaccine|September 21, 2010
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasisAlejandro Llanos-Cuentas, Wessmark Calderón, María Cruz, et al.
Pageof 27